Corcept Therapeutics + PPD Biotech Solutions
As Corcept Therapeutics leads the way in researching and developing cortisol modulators, the PPD™ clinical research business of Thermo Fisher Scientific is excited to be part of your journey. We appreciate the opportunity to be your trusted partner in the upcoming Expanded Access Programs and believe this is just the beginning of how we can collaborate for Corcept Therapeutic’s success.
As your CRO partner, our goal is to deliver innovative solutions tailored to your needs, with a focus on collaboration, forward thinking, data quality, speed and agility. Our combined CDMO and CRO offerings enhance our ability to support you under one roof. We share your dedication to your patients’ health and your professional success and are fully committed to support your voyage of unlocking the potential of cortisol modulation to revolutionize the treatment of serious diseases.
Why partner with us?
We understand the unique challenges Corcept Therapeutics may face in developing and commercializing innovative therapies. With 80% of our customers returning for repeat business and 65% of our revenue coming from biotech companies, we pride ourselves on building strong relationships. We achieve this through a commitment to true partnership, innovation, flexibility and trust.
What you can expect from our team:
- Elevate your outcomes: Achieve clinical and operational excellence at every stage
- Accelerate your timeline: Minimize delays with efficient project management and execution
- Simplify your journey: Let us handle the complexities so you can focus on breakthrough science
We’re more than a service provider — we’re your partner in innovation
Our specialized teams bring deep industry knowledge and a commitment to Corcept Therapeutics’ goals, offering:
- Dedicated experts: Medical officers and portfolio leads who work as an extension of your team
- Custom governance: Tailored structures that adapt to your specific needs, ensuring prioritization and focus
- Strategic insights: Proven methodologies to optimize your clinical strategy and meet regulatory and investor expectations
We will provide consistent and transparent financial reporting
With monthly and quarterly forecasts, customized cashflow assessments, and detailed portfolio views, we enable you to:
- Avoid surprises: Plan budgets efficiently and anticipate financial needs
- Strengthen investor confidence: Deliver clear, actionable financial insights that align with Corcept’s milestones
- Optimize decision-making: Access precise financial data to make informed, strategic choices that accelerate your program’s success
The path to success in biotech is personal and challenging, which is why we’re here to walk it with you.
From proving product viability to navigating complex regulatory pathways, our mission is to simplify your drug development journey while driving results. We understand the importance of a pipeline built for patients, ensuring that every step is designed with the patient in mind.
Therapeutic area spotlight
Oncology
With experience in more than 700 hematology and oncology clinical trials, we have expertise across the full range of cancer therapies.
For more than 30 years, drug developers have partnered with us to develop and commercialize their oncology treatments. Success in oncology clinical research requires partners with a deep understanding of the disease and an unrelenting dedication to developing the solutions patients need. In the past five years alone, we have supported 34 oncology drug approvals in the U.S. — including three first-in-class products.
studies
sites
patients
Neurology
Your commitment to developing meaningful solutions to neuroscientific and psychiatric challenges is shared by our experts.
In the past five years, we have supported more than 450 clinical studies in neuroscience and over 50 rare neurological disorder studies, including over 60,000 patients and 9,000 sites around the globe. Our experience also includes 50 psychiatry trials.
Seven of the 10 U.S. Food and Drug Administration (FDA)-approved neuroscience therapies approved in the past five years have been supported by our teams. Our experience spans every stage of neuroscience R&D.
studies
sites
patients
Endocrinology
We help clients make the right moves to overcome the unique challenges of trials with strong expertise in endocrinology. From the world’s largest innovators to emerging biotech companies, we work shoulder-to-shoulder with clients to get their life-changing products to market quickly. With experience in over 150+ rare metabolic and endocrine studies, we ensure your trials are managed with the highest level of expertise and efficiency.
studies
sites
patients
Cardiovascular
Cardiovascular disease claims more lives globally than any other cause, yet new treatments have steadily declined for two consecutive decades, leaving a significant void. Your compound holds the potential to meet the unmet need for safer and more effective cardiovascular drugs. We can help navigate the multitude of challenges that have impeded cardiovascular drug development and approval. With experience running over 75 cardiovascular trials in the past 5 years, we are well-equipped to support your journey from concept to market.
studies
sites
patients
Accelerator™ Drug Development: Integrated CDMO and CRO solutions for rapid, safe therapeutic delivery
In the biotech industry, delivering essential treatments quickly and safely demands a comprehensive approach to reduce delay, complexity, and risk. Accelerator™ Drug Development by Thermo Fisher Scientific offers 360˚ CDMO and CRO solutions, streamlining the drug development journey under one roof to speed up patient access to treatments. Through our integrated CDMO and CRO solutions, we provide a complete suite of services to take your asset from research to market, streamlining timelines, proactively mitigating risks, eliminating handoffs between multiple vendors, simplifying contracts and centralizing program management.
